title: Effects of added antibiotics on the basic properties of anti-washout-type fast-setting calcium phosphate cement.
abstract: The effect of added antibiotics on the basic properties of anti-washout-type fast-setting calcium phosphate cement (aw-FSCPC) was investigated in a preliminary evaluation of aw-FSCPC containing drugs. Flomoxef sodium was employed as the antibiotic and was incorporated into the powder-phase aw-FSCPC at up to 10%. The setting time, consistency, wet diametral tensile strength (DTS) value, and porosity were measured for aw-FSCPC containing various amounts of flomoxef sodium. X-ray diffraction (XRD) analysis was also conducted for the identification of products. To evaluate the drug-release profile, set aw-FSCPC was immersed in saline and the released flomoxef sodium was determined at regular intervals. The spread area of the cement paste as an index of consistency of the cement increased progressively with the addition of flomoxef sodium, and it doubled when the aw-FSCPC contained 8% flomoxef sodium. In contrast, the wet DTS value decreased with increase in flomoxef sodium content. Bulk density measurement and scanning electron microscopic observation revealed that the set mass was more porous with the amount of flomoxef sodium contained in the aw-FSCPC. The XRD analysis revealed that formation of hydroxyapatite (HAP) from aw-FSCPC was reduced even after 24 h, when the aw-FSCPC contained flomoxef sodium at > or = 6%. Therefore, the decrease of wet DTS value was thought to be partly the result of the increased porosity and inhibition of HAP formation in aw-FSCPC containing large amounts of flomoxef sodium. The flomoxef sodium release from aw-FSCPC showed the typical profile observed in a skeleton-type drug delivery system (DDS). The rate of drug release from aw-FSCPC can be controlled by changing the concentration of sodium alginate. Although flomoxef sodium addition has certain disadvantageous effects on the basic properties of aw-FSCPC, we conclude that aw-FSCPC is a good candidate for potential use as a DDS carrier that may be useful in surgical operations.
authors.affiliation: First Department of Oral and Maxillofacial Surgery, School of Dentistry, Tokushima University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Takechi
authors.forename: Y
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: K
authors.initials: K
authors.lastname: Ishikawa
authors.forename: M
authors.initials: M
authors.lastname: Nagayama
authors.forename: M
authors.initials: M
authors.lastname: Kon
authors.forename: K
authors.initials: K
authors.lastname: Asaoka
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D001672:Biocompatible Materials; D002130:Calcium Phosphates; D002511:Cephalosporins / Q000494:pharmacology*; D003738:Dental Cements; D016503:Drug Delivery Systems; D012995:Solubility; D013718:Tensile Strength; D013997:Time Factors; D014961:X-Ray Diffraction
chemical_list: D001672:Biocompatible Materials; D002130:Calcium Phosphates; D002511:Cephalosporins; D003738:Dental Cements; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous; C045693:flomoxef